American Journal of Medical Case Reports
ISSN (Print): 2374-2151 ISSN (Online): 2374-216X Website: http://www.sciepub.com/journal/ajmcr Editor-in-chief: Samy, I. McFarlane
Open Access
Journal Browser
Go
American Journal of Medical Case Reports. 2018, 6(3), 47-49
DOI: 10.12691/ajmcr-6-3-2
Open AccessArticle

Investigation of Ocular Manifestation in Patients Diagnosed with Multiple Sclerosis Based on the Manifestation and Demographic and Geographic Data

Zahra Janamiri1, , Yousef Moghimi Boldaji2 and Fardis Mosayebian1

1Department of Radiology Technology, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

2Department of Medical Physics, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

Pub. Date: April 21, 2018

Cite this paper:
Zahra Janamiri, Yousef Moghimi Boldaji and Fardis Mosayebian. Investigation of Ocular Manifestation in Patients Diagnosed with Multiple Sclerosis Based on the Manifestation and Demographic and Geographic Data. American Journal of Medical Case Reports. 2018; 6(3):47-49. doi: 10.12691/ajmcr-6-3-2

Abstract

Introduction: Multiple sclerosis (MS) is an autoimmune inflammatory condition which attacks and demyelinate central nervous system neurons with variable degree which causes significant disability in these patients. In this study, we plan to investigate ocular manifestation and prevalence of these symptoms in patients diagnosed with MS. Methods: We have enrolled 100 patients with confirmed diagnosis of MS, in a retrospective study from neurology clinic of a private hospital in Tehran, from 2015 to 2016. We have reviewed the thorough neurological examination and visual assessment of these patients. Also, demographic data of these patients were recorded for further analysis. We have performed statistical analysis using SPSS version 16 and Stuent T-test and Chi-square test for variables analysis. Results: Of all patients, 85 cases were female and 15 were male, with mean age of 35.2 years. We have found atrophy of the disc followed by optic neuritis in 32% and 19% respectively. Also, retrobulbar neuritis and papillitis were among less common manifestations, counting as 13% and 8% respectively. Most of the ocular manifestation were consistent with some demographic and geographic factors, such as age (most common in patients under 34 years old), female gender and patients not living in city areas. Also, patients with their disease initially started less than 22 years showed increased frequency of nystagmus and optic disc atrophy, while defect in color vision were more common in patients with initial disease initiation after 22 years old (P value < 0.05). Conclusion: Patients with MS may have various presentations of neurological abnormalities, which ocular manifestations is one of the most important and initial warning signs. We have found that optic disc atrophy and optic neuritis are among the most common presentations of MS, and neurologists should consider demographic and geographic parameters of patients.

Keywords:
multiple sclerosis ocular manifestation optic disc atrophy optic neuritis demographic data geographical data

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  Polman, C.H., Reingold, S.C., Banwell, B., Clanet, M., Cohen, J.A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., Lublin, F.D., “Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria,” Annals of neurology, 69(2). 292-302. 2011.
 
[2]  Lublin, F.D., Reingold, S.C., “Defining the clinical course of multiple sclerosis results of an international survey,” Neurology, 46(4). 907-11. 1996.
 
[3]  Cortese, I., Chaudhry, V., So, Y.T., Cantor, F., Cornblath, D.R., Rae-Grant, A., “Evidence-based guideline update: Plasmapheresis in neurologic disorders Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology,” Neurology, 76(3). 294-300. 2011.
 
[4]  Calabresi, P.A., Kieseier, B.C., Arnold, D.L., Balcer, L.J., Boyko, A., Pelletier, J., Liu, S., Zhu, Y., Seddighzadeh, A., Hung, S., Deykin, A., “Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study,” The Lancet Neurology, 13(7). 657-65. 2014.
 
[5]  Valenzuela, R.M., Pula, J.H., Garwacki, D., Cotter, J., Kattah, J.C., “Cryptococcal meningitis in a multiple sclerosis patient taking natalizumab,” Journal of the neurological sciences, 340(1). 109-11. 2014.
 
[6]  Gold, R., Kappos, L., Arnold, D.L., Bar-Or, A., Giovannoni, G., Selmaj, K., Tornatore, C., Sweetser, M.T., Yang, M., Sheikh, S.I,, Dawson, K.T., “Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis,” New England Journal of Medicine, 367(12). 1098-107. 2012.
 
[7]  Cohen, J.A., Coles, A.J., Arnold, D.L., Confavreux, C., Fox, E.J., Hartung, H.P., Havrdova, E., Selmaj, K.W., Weiner, H.L., Fisher, E., Brinar, V.V., “Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial,” The Lancet, 380(9856). 1819-28. 2012.
 
[8]  Nielsen, N.M., Westergaard, T., Rostgaard, K., Frisch, M., Hjalgrim, H., Wohlfahrt, J., Koch-Henriksen, N., Melbye, M., “Familial risk of multiple sclerosis: a nationwide cohort study,” American journal of epidemiology, 162(8). 774-8. 2005.
 
[9]  Kampman, M.T., Brustad, M., “Vitamin D: a candidate for the environmental effect in multiple sclerosis–observations from Norway,” Neuroepidemiology, 30(3). 140-6. 2008.
 
[10]  Williamson, D.M., Noonan, C.W., Henry, J.P., Wagner, L., Indian, R., Lynch, S.G., Neuberger, J.S., Schiffer, R., Trottier, J., Marrie, R.A., “Peer Reviewed: The Prevalence of Multiple Sclerosis in 3 US Communities,” Preventing chronic disease, 7(1). 2010.
 
[11]  Bonhomme, G.R., Waldman, A.T., Balcer, L.J., Daniels, A.B., Tennekoon, G.I., Forman, S., Galetta, S.L., Liu, G.T., “Pediatric optic neuritis Brain MRI abnormalities and risk of multiple sclerosis,” Neurology, 72(10). 881-5. 2009.
 
[12]  Seddighi, A.S., Seddighi, A., Behrouzian, S., Nikouei, A., “Simultaneous Presentation of Cerebellopontine Angle Pleomorphic Xanthoastrocytoma and Malignant Melanoma in a Known Case of Neurofibromatosis 1; Probable Role of BRAF Gene: A Case Report and Review of Literature,” International Journal of Cancer Management, 10(7). 2017.
 
[13]  Filippi M, Yousry TA, Alkadhi H, Stehling M, Horsfield MA, Voltz R. Spinal cord MRI in multiple sclerosis with multicoil arrays: a comparison between fast spin echo and fast FLAIR. Journal of Neurology, Neurosurgery & Psychiatry. 1996 Dec 1; 61(6): 632-5.
 
[14]  Seddighi, A., Nikouei, A., Seddighi, A.S., Zali, A.R., Tabatabaei, S.M., Sheykhi, A.R., Yourdkhani, F., Naeimian, S., “Peripheral nerve injury: a review article,” International Clinical Neuroscience Journal, 3(1). 1-6. 2016.